We are live on ! Find out more
BOLT icon

Bolt Biotherapeutics
BOLT

61 hedge funds and large institutions have $54.8M invested in Bolt Biotherapeutics in 2022 Q2 according to their latest regulatory filings, with 16 funds opening new positions, 14 increasing their positions, 19 reducing their positions, and 18 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

0.31% less ownership

Funds ownership: 3.89% → 3.58% (-0.31%)

6% less funds holding

Funds holding: 65 → 61 (-4)

11% less first-time investments, than exits

New positions opened: 16 | Existing positions closed: 18

26% less repeat investments, than reductions

Existing positions increased: 14 | Existing positions reduced: 19

35% less capital invested

Capital invested by funds: $84.8M → $54.8M (-$30M)

Holders
61
Holders Change
-4
Holders Change %
-6.15%
% of All Funds
1.03%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
16
Increased
14
Reduced
19
Closed
18
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
NM
Newtyn Management
New York
+$1.45M
2
RCM
RA Capital Management
Massachusetts
+$874K
3
Assenagon Asset Management
Assenagon Asset Management
Luxembourg
+$535K
4
Renaissance Technologies
Renaissance Technologies
New York
+$482K
5
TCM
Tang Capital Management
California
+$388K

Top Sellers

Rank Fund Capital Flow
1
ESCM
Echo Street Capital Management
New York
-$5.49M
2
Holocene Advisors
Holocene Advisors
New York
-$3.19M
3
EAM
Eventide Asset Management
Massachusetts
-$2.36M
4
BlackRock
BlackRock
New York
-$2.26M
5
AC
Armistice Capital
New York
-$1.1M
Name Holding Trade Value Shares
Change 		Change in
Stake
NHAS
1
Novo Holdings A/S
Denmark
$9.19M – – –
VC
2
Vivo Capital
California
$7.9M – – –
Citadel Advisors
3
Citadel Advisors
Florida
$5.62M +$6.13K +158 +0.1%
SI
4
Sofinnova Investments
California
$5.62M – – –
SCM
5
Suvretta Capital Management
New York
$4.55M – – –
PBPIA
6
Pivotal bioVenture Partners Investment Advisor
California
$3.86M – – –
NFGH
7
Nan Fung Group Holdings
Hong Kong
$2.38M – – –
SB
8
Samsara BioCapital
California
$2.14M – – –
Vanguard Group
9
Vanguard Group
Pennsylvania
$1.81M +$81.5K +2,099 +5%
NM
10
Newtyn Management
New York
$1.53M +$1.45M +37,413 New
BOTOTLSJU
11
Board of Trustees of The Leland Stanford Junior University
California
$1.47M – – –
Renaissance Technologies
12
Renaissance Technologies
New York
$1.1M +$482K +12,424 +86%
BlackRock
13
BlackRock
New York
$918K -$2.26M -58,102 -72%
RCM
14
RA Capital Management
Massachusetts
$918K +$874K +22,507 New
HCM
15
Hawkeye Capital Management
Florida
$847K – – –
Morgan Stanley
16
Morgan Stanley
New York
$838K -$25.1K -646 -3%
Assenagon Asset Management
17
Assenagon Asset Management
Luxembourg
$562K +$535K +13,778 New
TCM
18
Tang Capital Management
California
$408K +$388K +10,000 New
Millennium Management
19
Millennium Management
New York
$391K +$372K +9,593 New
EC
20
EcoR1 Capital
California
$306K – – –
Geode Capital Management
21
Geode Capital Management
Massachusetts
$290K -$358K -9,224 -56%
OMC
22
Oasis Management Company
Cayman Islands
$219K +$209K +5,375 New
E
23
Ergoteles
New York
$216K +$205K +5,283 New
Russell Investments Group
24
Russell Investments Group
United Kingdom
$196K +$187K +4,805 New
Fidelity Investments
25
Fidelity Investments
Massachusetts
$162K +$233 +6 +0.2%
1
2 3 4

BOLT Hedge Fund Activity: Q2 2022 in Review

61 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Bolt Biotherapeutics (BOLT) for Q2 2022, worth a combined $54.8M — down 35% from $84.8M a quarter earlier.

Sellers outnumbered buyers: 18 funds closed out of BOLT and 16 opened new positions — a net loss of 2 holders — while 19 trimmed existing stakes and 14 added.

The largest buyer was Newtyn Management, opening a new position worth an estimated $1.45M. The largest seller was Echo Street Capital Management, exiting entirely with an estimated $5.49M sold.

  • 61 institutional investors held Bolt Biotherapeutics (BOLT) as of Q2 2022, down from 65 in Q1 2022.
  • Funds reported $54.8M of Bolt Biotherapeutics stock for Q2 2022, down 35% quarter-over-quarter.
  • 16 funds opened new Bolt Biotherapeutics positions in Q2 2022 and 18 closed out, a net change of -2 holders.
  • The largest Bolt Biotherapeutics buyer in Q2 2022 was Newtyn Management, an estimated $1.45M added.
  • The largest Bolt Biotherapeutics seller in Q2 2022 was Echo Street Capital Management, an estimated $5.49M sold.

Based on aggregated 13F filings for Q2 2022.